The Division of Hematologic Malignancies 2 (DHM2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologic Licensing Applications (BLAs) for Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, and other plasma cell malignancies.
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Hematologic Malignancies 2 (DHM2)
5901-B Ammendale Road
Beltsville, MD 20705-1266
Phone: (301) 796-7550
Fax: (301) 796-9845